Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells

OBJECTIVES: Triple negative breast cancer (TNBC) lacks specific drug targets and remains challenging. Palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor is approved for metastatic estrogen receptor (ER)-positive and human epithermal growth factor 2 (HER2)-negative breast cancer. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chun-Yu, Lau, Ka-Yi, Hsu, Chia-Chi, Chen, Ji-Lin, Lee, Chia-Han, Huang, Tzu-Ting, Chen, Yi-Ting, Huang, Chun-Teng, Lin, Po-Han, Tseng, Ling-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737960/
https://www.ncbi.nlm.nih.gov/pubmed/29261702
http://dx.doi.org/10.1371/journal.pone.0189007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737960/
https://www.ncbi.nlm.nih.gov/pubmed/29261702
http://dx.doi.org/10.1371/journal.pone.0189007

Ejemplares similares